Roche unveils new PCR test to improve Vaginitis Diagnosis in countries following CE Mark

On the other hand, the cobas BV/CV assay delivers accurate and specific results, allowing healthcare professionals to deliver targeted therapies to patients more quickly, the release stated.

“The cobas BV/CV assay protects women from the risks of delayed or incorrect treatment, leading to faster relief from symptoms and a reduced likelihood of serious future complications,” said Matt Sause, CEO of Roche Diagnostics. “At the same time, it improves efficiency for healthcare services by accurately identifying the most common causes of inflammation or infection in a single test.”

Bacterial vaginosis impacts approximately 25% of women of reproductive age, while up to 75% of women experience candida vaginitis at least once in their lifetime. Vaginal symptoms are one of the most common reasons women visit the doctor each year. Diagnosis of these conditions can be challenging as symptoms are often non-specific, and traditional testing methods, such as microscopy, lack precision. Causing uncomfortable and sometimes distressing symptoms such as itching, burning, discharge, and irritation, BV and CV infections are also associated with an increased risk of having a sexually transmitted infection (STI).

The global sexual health market segment is valued at CHF 1.1 bn, with an annual growth rate of 11%. Of this market segment, vaginitis is the primary growth driver with a yearly growth rate of 26%. The cobas BV/CV assay further expands Roche Diagnostics’ established sexual health portfolio. By enabling testing for BV and CV alongside a broad range of sexually transmitted infections, including Chlamydia, Gonorrhoea, Trichomonas, and Mycoplasma genitalium, using the same sample, the assay enhances the capabilities of the cobas 5800/6800/8800 systems.

The cobas BV/CV assay is now available in countries accepting the CE Mark.